Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
Business Wire•12/11/2026•16:01 ET
0
Key Highlights
- ➤2026 revenue $450.8M, down from $829.4M in 2025
- ➤2026 net loss $724.2M versus $1.6M loss in 2025
- ➤REDEMPLO prescriptions grew 63% quarter over quarter
- ➤FDA STAR entry grants plozasiran a six-month Priority Review for sHTG
- ➤New $400M term loan lowers interest rate to SOFR plus 5.50%
Expert Statements
Christopher Anzalone, President and CEO of Arrowhead Pharmaceuticals
“Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there is now a company that is beginning to translate promise into real patient outcomes and the potential for durable shareholder value growth”
Christopher Anzalone, President and CEO of Arrowhead Pharmaceuticals
“We are building a commercial business around REDEMPLO®, we delivered pivotal data we believe is needed to pursue a much larger market in severe hypertriglyceridemia, we have recently submitted an sNDA to the U.S. FDA, and we have demonstrated new capabilities that substantially expand what our RNAi platform can do. I believe we approach 2027 with the strongest combination of near-term commercial opportunity and scientific capability in our history.”
Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
Conference Call and Webcast Today, November 12, 2026, at 4:30 p.m. ET
Get started
Create a free account to read the full story.